Havells gathers speed to hit all-time high; analysts divided over its prospects

Shares of Havells India Ltd surged on Thursday after the company reported its Q4 financial results. The stock has hit a fresh high at ₹1,706.85 and traded at ₹1,669.20 on the NSE, up 0.31 per cent as of 1.03 pm. .

Shares of Havells India Ltd surged on Thursday after the company reported its Q4 financial results. The stock has hit a fresh high at ₹1,706.85 and traded at ₹1,669.20 on the NSE, up 0.31 per cent as of 1.03 pm. . 

The brokerages’ call for the stock gained mixed reactions, divided over the company’s prospects.

The company on Tuesday reported an increase of 24.76 per cent in its consolidated net profit to ₹446.70 crore for the March 2024 quarter as against ₹358.04 crore in the March quarter a year ago.

Global brokerage Nuvama and Jefferies assigned/ maintained the ‘hold’ rating, while UBS and HSBC assigned ‘buy’ rating with an increased target price of ₹2,040 and ₹1,800, respectively. 

JM Financial maintained its ‘buy’ call with a revised target price of ₹1,680 as against ₹1,580 earlier. “We raise our EPS estimates by 11 per cent /6 per cent for FY25/26 respectively to reflect a) better-than-expected margin performance in Lloyd (-1 per cent vs. -2 per cent earlier for FY25; 2.5 per cent in FY26 vs. 2 per cent earlier), and b) modest improvement of 30bps in ex-Lloyd businesses. We revise our estimates by 8%/5% for FY25/26 respectively to reflect margin uptick,” the report said.

It also pointed out the delayed recovery in demand and heightened competitive intensity, particularly in RAC, as key risks. 

Meanwhile, CLSA downgraded the stock to ‘sell’ and fixed the target price at ₹1,560, noting that Q4 numbers were ahead of estimates at better margins, while the top line was lower.

Domestic brokerage Motilal Oswal downgraded the stock to neutral. However, the brokerage raised the EPS estimates for FY25/FY26 by 4 per cent/5 per cent to account for better margins in the cables and switchgear businesses. “We value the stock at 55x FY26E EPS to arrive at our target price of ₹1,780 with a 7 per cent potential upside,” it said. 

Analysts of Motilal Oswal believe that investments in strengthening the brand equity of Lloyd and increasing the distribution network would benefit the company in the long run. 

Citi has also maintained its neutral stance with a target price at ₹1,814.

Meanwhile, the analyst of Prabhudas Lilladher maintained ‘accumulate’ rating at a DCF-based target price of ₹1,774 (earlier ₹1681), which implies 54x FY26 EPS.

“We believe the company to focus on growth in the coming year with restricted margins. We estimate Revenue/EBITDA/PAT CAGR of 15.6%/24.5%/26.8% for FY24-26E with ECD/Cables/Lloyd segments revenue CAGR of 13.5%/18.0%/16.2% over FY24-26E and EBITDA margin to reach 11.5% by FY26E (+160bps),” Praveen Sahay of Prabhudas Lilladher said.

Like (0)
Previous May 3, 2024 2:15 pm
Next May 3, 2024 2:15 pm

Related posts

  • Nikola rose nearly 4% before the market opened and received orders for 100 hydrogen fuel cell electric vehicles

    Gelonghui, May 22 | U.S. electric truck manufacturer Nikola (NKLA.US) U.S. stocks rose nearly 4% before the market opened, at $0.559

    US stock market May 22, 2024
  • Sensex, Nifty open higher; realty stocks decline over 1%

    Domestic benchmark indices opened higher on Monday. BSE Sensex traded at 74,124.96, higher by 394.80 pts or 0.54 per cent as of 9.40 am and Nifty 50 traded at 22,500.10, up 80.15 pts or 0.36 per cent.

    US stock market April 29, 2024
  • Zydus Lifesciences and MSN partner for US generic Cabozantinib supply

    Zydus Lifesciences Ltd.’s shares were up by 2.25 per cent to ₹1,031.95 on the BSE. The company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets, a generic version of CABOMETYX, intended for the US market.

    US stock market May 17, 2024
  • Market Today: Sensex, Nifty open higher Shriram Finance, Hindalco, BPCL among top gainers

    BSE Sensex traded at 72,902.15, higher by 126.02 pts or 0.17 per cent as of 9.20 am; and Nifty 50 traded at 22,148.70, up 44.65 pts or 0.2 per cent.

    US stock market May 14, 2024
  • Mutual funds’ incentive for small city outreach in limbo after a year

    More than a year after suspending the beyond-top-30 incentives, the capital market regulator SEBI has shelved the decision to revive it, as the industry could not device effective checks and balances to prevent its misuse. Last February, SEBI directed mutual fund companies to keep the small-town linked sop of additional expense ratio in abeyance, citing a lack of a system-driven mechanism to check the abuse of the incentive structure. To promote financial inclusion through increased penetration of mutual funds and in investors interest, SEBI had permitted fund houses an additional expense ratio of 30 basis points on new inflows (up to Rs 2 lakh) from retail investors for encouraging mutual funds garnering funds from B-30 cities and energising the distribution network. Despite discontinuation of the incentive, the inflow from the smaller cities has been very strong due to outreach of the mutual fund industry amid intense competition and hence SEBI is not very keen on re-looking at reviving this sop, said an executive of a leading fund house. Read: Now, hinterland driving AUM rise in MFs Nirav Karkera, Head of…

    US stock market May 23, 2024
  • Novavax gains about 3.5% pre-market after hedge fund investors recommend two new director candidates

    Glonghui, April 15 | US hedge fund Shah Capital has recommended that Covid-19 vaccine maker Novavax appoint two new independent directors, Suresh Katta and Venkat Peri, to its board. Shah Capital, which owns about 6.7% of Novavax’s outstanding common stock, said the low share price reflected the board and management’s failure to capitalize on many important competitive advantages and seize opportunities in the overall market. “We welcome the views of our shareholders and value their input on our strategy,” Novavax said in a statement. Novavax is one of the most shorted stocks on the Nasdaq (16175.0941, 0.00, 0.00%) and is currently trading near all-time lows. As of last trading day’s close, the stock had fallen more than 53% in the past 12 months. The stock rose about 3.5% premarket.

    US stock market April 15, 2024